Decentralized Manufacturing for Cell Therapies

3pm Chair Introduction

Miguel Forte, Chief Executive Officer, Kiji Therapeutics, President-Elect, ISCT

3.05pm Presentation Title: Point of Care Manufacturing at an Academic Center: Increasing Accessibility to Cell Therapies

• Discuss benefits of point of care manufacturing over traditional third-party manufacturing paradigms
• Review outcomes with CliniMACS Prodigy Manufacturing at an Academic Center

Nirav Shah, Associate Professor of Medicine, Medical College Wisconsin

3.20pm Presentation: Enabling Decentralized Manufacturing By Metabolic Sensing And Control, Machine Learning And AI. The ADVA X3 Case Study

• Taking the human error and variation out of cell therapy manufacturing
• Automating cell therapy manufacturing based on metabolic sensing and feedback loops.
• Ensuring the correct process outcome using online data and machine learning.
• Process optimization and predictability using AI
• Adva X3 CAR T case studies

Ohad Karnieli, Chief Executive Officer, ADVA

3.35pm Presentation: Joining Forces For Distributed Manufacturing - Here We Are

• Why
• How
• Who
• Status

Dorothea Ledergerber, Chief Technical Officer, Tigen

3.50pm Presentation Title: The Inevitability of Decentralizing Advanced Therapies Manufacturing (and the tug-of-war on the way to this future)

• Where is the line between decentralized, distributed, and point-of-care manufacturing?
• Does the point-of-care manufacturing model require hospitals to manufacture?
• Does decentralized or POC manufacturing require a different biopharma business model?

Lee Buckler, Senior Vice President, Blood Centers for America

4.05pm Panel Discussion

Joined by all session participants